Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection

Journal of Clinical Oncology

Volumn 21, Issue 12, 2003, Pages 2312-2319

  Nam, Robert K ^a   Zhang, William W ^a   Trachtenberg, John ^a   Diamandis, Eleftherios ^a   Toi, Ants ^a   Emami, Marjan ^a   Ho, Minnie ^a   Sweet, Joan ^a   Evans, Andrew ^a   Jewett, Michael A S ^a   Narod, Steven A ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 2; UNCLASSIFIED DRUG; PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN;

ALLELE; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; GENE EXPRESSION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; ADULT; AGED; BLOOD; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; PREDICTION AND FORECASTING; PROSTATE TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE KALLIKREINS;

EID: 0037811747     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.007     Document Type: Article

References (44)

1. Potosky AL, Miller BA, Albertsen PC, et al: The role of increasing detection in the rising incidence of prostate cancer. JAMA 273:548-552, 1995
2. National Cancer Institute of Canada: Canadian Cancer Statistics 2000. Toronto, Canada, National Cancer Institute of Canada, 2000
3. von Eschenbach A, Ho R, Murphy GP, et al: American Cancer Society guidelines for the early detection of prostate cancer. Cancer 80:1805-1807, 1997
4. Stamey TA, Yang N, Hay R, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-915, 1987
5. Vanchieri C: Prostate cancer screening trials: Fending off critics to recruit men. J Natl Cancer Inst 90:10-12, 1998
6. Schroder FH, Bangma CH: The European randomized study of screening for prostate cancer (ERSPC). Br J Urol 79:68-71, 1997
7. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273:289-294, 1995
8. Catalona WJ, Smith DS, Ratiff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948-954, 1993
9. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991
10. Nam RK, Klotz LH, Jewett MAS, et al: PSA velocity as a measure of the natural history of prostate cancer: Defining a "rapid riser" subset. Br J Urol 81:100-104, 1998
11. Catalona WJ, Southwick PC, Slawin KM, et al: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56:255-260, 2000
12. Djavan B, Ravery V, Zlotta A, et al: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop? J Urol 166:1679-1683, 2001
13. Keetch DW, Catalona WJ, Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151:1571-1574, 1994
14. Giovannucci E, Stampfer MJ, Krithivas K, et al: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 94:3320-3323, 1997
15. Ingles SA, Ross RK, Yu MC, et al: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89:166-170, 1997
16. Nam RK, Toi A, Vesprini D, et al: V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 57:199-204, 2001
17. Gsur A, Bernhofer G, Hinteregger S, et al: A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 87:434-437, 2000
18. Rebbeck TR, Jaffe JM, Walker AH, et al: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90:1225-1229, 1998
19. Xue W, Irvine RA, Yu MC, et al: Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60:839-841, 2000
20. Rebbeck TR, Walker AH, Jaffe JM, et al: Glutathione S-transferase-mu (GSTM1) and theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev 8:283-287, 1999
21. Nam RK, Diamandis EP, Toi A, et al: Serum human glandular kallikrein-2 (hK2) protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 18:1036-1042, 2000
22. Herrala A, Kurkela R, Porvari K, et al: Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein. Clin Chem 43:279-284, 1997
23. Barry MJ, Fowler FJJ, O'Leary MP, et al: The American Urological Association symptom index for benign prostatic hyperplasia: The Measurement Committee of the American Urological Association. J Urol 148:1549-1557, 1992
24. Schedlich L, Bennets BH, Morris BJ: Primary structure of a human glandular kallikrein gene. DNA 6:429-437, 1987
25. Black MH, Magklara A, Obiezu C, et al: Development of an ultrasensitive immunoassay for human glandular kallikrein (hK2) with no cross-reactivity from prostate-specific antigen (PSA). Clin Chem 45:790-799, 1999
26. Finlay JA, Day JR, Evans CL, et al: Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin Chem 47:1218-1224, 2001
27. Hsing AW, Chen C, Chokkalingam AP, et al: Polymorphic markers in the SRD5A2 gene and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 10:1077-1082, 2001
28. Carpten J, Nupponen N, Isaacs S, et al: Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30:181-184, 2002
29. Vesprini D, Nam RK, Trachtenberg J, et al: HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 68:912-917, 2001
30. Suarez BK, Gerhard DS, Lin J, et al: Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 61:4982-4984, 2001
31. Wang L, McDonnell SK, Elkins DA, et al: Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 61:6494-6499, 2001
32. Young C-F, Andrews PE, Montgomery BT, et al: Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31:818-824, 1992
33. Henttu P, Lukkarinen O, Vihko P: Expression of the gene coding for human prostate specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 45:654-660, 1990
34. Murtha P, Tindall DJ, Young C-F: Androgen induction of a human prostate-specific kallikrein hKLK2: Characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 32:6459-6464, 1993
35. Reigman PH, Vlietstra RJ, Suurmeijer L, et al: Characterization of the human kallikrein locus. Genomics 14:6-11, 1992
36. Lovgren J, Rajakoski K, Karp M, et al: Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238:549-555, 1997
37. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76:1899-1903, 1985
38. Kwiatkowski MK, Recker F, Piironen T, et al: In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic 'gray zone' of total PSA 4 to 10 ng/mL. Urology 52:360-365, 1998
39. Becker C, Piironen T, Pettersson K, et al: Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate specific antigen levels 3.0 ng/mL or greater. Urology 55:694-699, 2000
40. Partin AW, Catalona WJ, Finlay JA, et al: Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis. Urology 54:839-845, 1999
41. Finlay JA, Day JR, Evans CL, et al: Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin Chem 47:1218-1224, 2001
42. Frenette G, Tremblay RR, Lazure C, et al: Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 71:897-899, 1997
43. Fortier AH, Nelson BJ, Grella DK, et al: Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 91:1635-1640, 1999
44. Narod SA, Dupont A, Cusan L, et al: The impact of family history on early detection of prostate cancer. Nat Med 1:99-101, 1995